Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

RLYB 11.25.2024

Full Press ReleaseSEC FilingsOur RLYB Tweets

About Gravity Analytica

Recent News

  • 01.10.2025 - Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
  • 12.10.2024 - Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
  • 12.04.2024 - be 2024 Evercore ISI HealthCONx Conference

Recent Filings

  • 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
PDF Version

-- Webcast to be held onMonday, December 2, 2024at8:30 AM Eastern Time--

NEW HAVEN, Conn.--(BUSINESS WIRE)--Nov. 25, 2024--Rallybio Corporation(Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the Company will host a webcast to provide a program update on RLYB116, its innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. The webcast will take place onMonday, December 2at8:30 AM Eastern Timeand will review recent manufacturing process enhancements, biomarker characterization analyses, and the Company’s future plans for the program.

Webcast Information

The live webcast may be accessed by visiting Rallybio’s website athttp://investors.rallybio.com. A replay and accompanying slides of the webcast will be available on theRallybiowebsite for 30 days following the event.

AboutRallybio

Rallybio(NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases.Rallybiohas built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, a C5 inhibitor that has the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.Rallybiois headquartered inNew Haven, Connecticut. For more information, please visitwww.rallybio.comand follow us onLinkedInandTwitter.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241122010570/en/

InvestorsSamantha TracyRallybio Corporation(475) 47-RALLY (Ext. 282)investors@rallybio.com

Kevin LuiPrecision AQ(212) 698-8691kevin.lui@precisionaq.com

MediaVictoria ReynoldsMission North(760) 579-2134rallybio@missionnorth.com

Source:Rallybio Corporation

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com